trial
as of 2026-07-01Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder
NCTId NCT03526354
at a glance
Phase 4 · Completed
Enrollment 50 (actual)
Sponsored by University of Massachusetts, Worcester
Primary completion 2024-02-29
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
50 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2018-06-19
Primary completion
2024-02-29
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
University of Massachusetts, WorcesterLead Sponsor
Massachusetts General HospitalCollaborator
University of North Carolina, Chapel HillCollaborator
Augusta UniversityCollaborator
Investigators
1
Xiaoduo Fan, MD, MPH, MSPrincipal Investigator
Sites
4 total
Augusta, United StatesBoston, United StatesWorcester, United StatesChapel Hill, United States
Facts & assertions
4 sourced
Enrollment
50
Phase
PHASE4
Primary Completion Date
2024-02-29
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
collaborator
indication
investigator
person